Skip to content

Quest Diagnostics

US · DGX #767 by market cap Listed 1996
258.28 -0.81 -0.31%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Fair Value how this is computed

Above fair value
118.66 fair value ≈ 161.18 203.71
  • Implied fair-value range of 118.66-203.71, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +60.2% above the average-multiple fair value of 161.18.

Valuation each multiple against its own 5-year range

P/B ratio 3.72 Expensive vs history 99th percentile
5-year average 2.68 · #23 of 41 in Diagnostics & Research
P/E ratio 25.73 Expensive vs history 98th percentile
5-year average 18.42 · forward 24.16 · #3 of 20 in Diagnostics & Research
P/S ratio 2.40 Expensive vs history 99th percentile
5-year average 1.78 · forward 2.27 · #16 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
Quest Diagnostics (DGX) 28.42B 25.73 3.72 1.31%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value243.00 Economic moatNarrow UncertaintyMedium Capital allocationStandard

Trading 5.9% above Morningstar's fair value estimate.

Analyst note

Quest delivered third-quarter results that included revenue and earnings growth of 10% and 26%, respectively. Management indicated it estimates potential PAMA cuts in 2027 could amount to 1% of total revenue.

Why it matters: Quest has now delivered nine consecutive quarters of robust top-line growth, helped along by savvy collaborations as well as the generally strong medical utilization that started in 2024. We still expect solid volume even as Fresenius and Corewell Health initiatives roll into organic growth soon. Importantly, the firm has begun to demonstrate efficiencies with these two programs as they have taken hold, driving quarterly operating margin up by 180 basis points year over year. The Fresenius arrangement, in particular, offers potential for Quest to gain new nephrologist customers whose end-stage renal disease patients need lab testing every two to four weeks.

The bottom line: Our slight tweaks to our model to reflect Quest's ongoing strength in 2026 weren't material enough to shift our $243 per-share fair value estimate. We remain confident in Quest's significant cost advantage that supports its narrow moat. Though management raised full-year guidance again, we think shares barely moved because of the looming threat of PAMA cuts starting in 2027. At this point, we think there's a 50% chance that Congress would step in to delay the implementation of PAMA rate cuts again. Or, the cuts will go through by default if Congress is too distracted to intervene.

Coming up: We remain cautious about potential shrinkage of the pool of insureds, as subsidies on the marketplace exchanges have waned, new reporting requirements for Medicaid roll out, and some payers step back from Medicare Advantage. We're at the beginning of open enrollment, and the rolls of insureds could look different next year.

For the next round of PAMA reimbursement cuts, it's been a challenge to weigh the impact of data from the higher-cost hospital-based labs. On average, reimbursement for a test performed at a hospital-based lab is roughly 3 times the reimbursement for that same test to be conducted by Quest or Labcorp.

In the first round of reimbursement data collection for the last round of PAMA cuts in 2018-20, more than 90% of the data was provided by independent labs. On the whole, we estimate independent labs hold about 50% of US lab market share, and the remaining 50% is held by hospital-based labs. Thus, the first round of PAMA cuts was disproportionately skewed toward Quest and LabCorp rates, which are the lowest in the industry.

In the latest round of data collection, the Centers for Medicare and Medicaid Services recently revealed that 77% of the data was from independent labs. Again, this means the reimbursement rates would be highly skewed toward the lowest-cost producers, if the next round is implemented in 2027.

We find this highly disappointing because we already know that the steep cuts in the first round hurt patient access, especially in less dense areas, as smaller independent labs closed. We're also curious about whether the penalties for nonreporting that were written into the PAMA law will be enforced this time around. The penalties are steep—up to $10,000 per day for each omission, failure to report, and error in reported data. Last time, the hospital labs weren't penalized.

Having said that, as painful as any PAMA cuts might be, we think both Quest and LabCorp would come out the other side largely intact. Based on the last round of PAMA cuts, it was clear that the largest, lowest-cost labs were much better able to weather the reimbursement pressure than smaller independent labs.

Fair value

We're raising our fair value estimate to $243 per share, up from $204. While we haven't changed our underlying assumptions, we have incorporated our new approach to estimating the cost of capital. The increase was wholly driven by the 60-basis-point decline in weighted average cost of capital. We still expect that recent strengths in test volume can be maintained through 2026, aided by aggressive renegotiation of contracts with commercial payers to capture price increases. However, we hold more tempered expectations for the following four years as we anticipate some contraction in the insured population. This leads to our estimate for organic annual revenue growth of roughly 4% through 2030. We assume operating margins will expand steadily by roughly 300 basis points to 17% in our explicit forecast period.

During the height of the pandemic in 2020 through 2022, the PAMA cuts scheduled for 2021 were suspended, offering a bit of breathing room to the labs. Then, Congress took action at the end of 2021 to further delay the next reimbursement rate-setting cycle to 2022. This was followed by more delays in 2023, 2024, 2025, and 2026. In the most recent delay, implementation of the next round of PAMA cuts has been pushed off until 2027. This respite from PAMA cuts provides some stability in prices. If Congress can act on the proposed RESULTS legislation, it would reduce the prospect of another round of substantial PAMA cuts and put adjustments to Medicare reimbursement on a more gradual path. However, we're not particularly hopeful Congress can accomplish this by the end of the year.

Over the longer term, we think the company's focus on esoteric test business will pay off. With pharmaceutical and biotech companies aiming for personalized and targeted therapies, we expect a steady stream of new biomarker discovery and greater application of molecular diagnostics across the clinical spectrum. The latest development of blood tests to monitor for minimal residual disease among cancer survivors offers a new market to labs. This bodes well for Quest.

Economic moat

Quest's narrow moat is based on its vast national infrastructure in its core diagnostics labs business, which translates into a considerable cost advantage over smaller regional labs in the independent reference lab industry, as well as hospital-based labs. Compared with those other players, Quest offers compelling cost advantages thanks to its scale and volume. For example, tests at hospital labs typically cost 3 times more, on average, than the same test at Quest. This advantage becomes even more pronounced when throughput increases and translates into attractive operating leverage. Quest handled 244 million requisitions (each requisition often contains multiple tests) in 2025.

Additionally, the firm's nationwide footprint with an extensive network of 2,400 patient service centers and in-physician office services would be difficult to replicate from scratch. Quest's advantageous cost structure and national coverage are also appealing to the payers that structure reimbursement and policies to funnel patients to the large independent labs that offer lower prices. Payers would typically rather negotiate with the largest reference labs, including Quest, that provide the best geographic coverage for the insured base instead of cobbling together market-by-market coverage through multiple smaller regional labs.

We've seen large payers, including UnitedHealth and Elevance, begin to more assertively flex their muscle to direct more insureds to the lowest-cost labs and challenge the significantly higher prices that hospital-based labs demand for diagnostic tests. We wouldn't be surprised to see this trend continue as payers seek to lower medical costs. Finally, Quest's scale and reach make the company an attractive partner for the researchers who invent various diagnostic tests but have no distribution channels through which to sell the tests.

Although we had seen more aggressive price competition between Labcorp and Quest Diagnostics in the early 2000s, pricing has remained rational over the last 20 years and is even less likely to become irrational now that payers have shifted to adopt payment reforms. We think this reflects the influence of value-based healthcare reform, in the wake of the Affordable Care Act. It has become more economically attractive for payers to encourage patients to use any low-cost provider (instead of more expensive hospital-based labs) rather than pitting Labcorp and Quest against each other to eke out savings that also reduce patient access to lower-cost tests.

From an environmental, social, and governance perspective, Morningstar Sustainalytics pegs Quest's risk as low, and we concur. ESG risk that could affect the moats for the largest independent diagnostic reference labs is low. Some of the most vulnerable areas of risk include the high-quality standards labs must follow to ensure results are accurate and valid, as well as the risk of getting caught up in Medicare fraud through incorrect or overbilling.

As we saw with the Theranos debacle, inaccurate test results can lead to inappropriate medical treatment. However, Quest has robust, well-established processes to reduce risk in quality and billing. This contrasts with smaller independent labs, which have been more likely to stumble in these areas.

Bull case

Advances in technology and personalized medicine are increasing the number of complex esoteric and gene-based tests available to patients. These tests generally carry higher profit margins for Quest.

Quest has been actively seeking out hospital outreach programs to roll up. These acquisitions offer very attractive economics to Quest.

Though it is still early days for the adoption and reimbursement of Quest's molecular residual disease tests to monitor patients in cancer remission, we expect this will become standard of care over the long haul.

Bear case

If declines in the insured population are substantial, the resulting hit to test volume could drag down profitability for Quest.

If the impending cuts to Medicaid cause hospitals to close, that could narrow the pipeline of potential lab acquisition and collaboration targets for Quest.

On an anecdotal basis, we have consistently heard complaints from patients about poor service at Quest service centers.

By Debbie S. Wang

Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.

Quest Diagnostics discussion 0 comments

Add a comment